Welcome guest, Login | Register

Home


Rachel Perret

Education

Ph.D in Immunology, Malaghan Institute for Medical Research, University of Otago, 2008

Current position

Postdoctoral Fellow, Clinical Research Division, Fred Hutchinson Center for Cancer Research, Seattle, WA, USA (since 03/2013)

Publications

  1. Perret, R., Sierro, S. R., Botelho, N. K., Corgnac, S., Donda, A. and Romero, P. (2013). Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. Cancer Res 73(22): 6597-6608.
  2. Dudda, J. C.*, Salaun, B.*, Ji, Y.*, Palmer, D. C., Monnot, G. C., Merck, E., Boudousquie, C., Utzschneider, D. T., Escobar, T. M., Perret, R., Muljo, S. A., Hebeisen, M., Rufer, N., Zehn, D., Donda, A., Restifo, N. P., Held, W., Gattinoni, L.* and Romero, P.* (2013). MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity 38(4): 742-753.
  3. Corgnac, S., Perret, R., Derre, L., Zhang, L., Stirnemann, K., Zauderer, M., Speiser, D. E., Mach, J. P., Romero, P. and Donda, A. (2013). CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. Cancer Immunol Immunother 62(4): 747-760.
  4. Yang, J.*, Ma, J. Z.*, Qin, J., Richter, A., Perret, R., Finnberg, N. and Ronchese, F. (2012). Inefficient boosting of anti-tumor CD8+ T cells by DC vaccines is rescued by restricting T cell cytotoxic function. Oncoimmunol 1(9):1-10.
  5. Braun, M., Perret, R., Scholz, G. and Romero, P. (2012). Peptide and Protein-Based Cancer Vaccines. In: Curiel, T. J. (ed). Cancer Immunotherapy: Paradigms, Practice and Promise. Springer, 111-146.
  6. Castro-Diaz, N.*, Salaun, B.*, Perret, R.*, Sierro, S., Romero, J. F., Fernandez, J. A., Rubio-Moraga, A.* and Romero, P.* (2012). Saponins from the Spanish saffron Crocus sativus are efficient adjuvants for protein-based vaccines. Vaccine 30(2): 388-397
  7. Sierro, S. R., Donda, A., Perret, R., Guillaume, P., Yagita, H., Levy, F. and Romero, P. (2011). Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol 41(8): 2217-2228.
  8. Andrew, K. A., Simkins, H. M., Witzel, S., Perret, R., Hudson, J., Hermans, I. F., Ritchie, D. S., Yang, J. and Ronchese, F. (2008). Dendritic cells treated with lipopolysaccharide up-regulate serine protease inhibitor 6 and remain sensitive to killing by cytotoxic T lymphocytes in vivo. J Immunol 181(12): 8356-8362.
  9. Perret, R. and Ronchese, F. (2008). Effector CD8+ T cells activated in vitro confer immediate and long-term tumor protection in vivo. Eur J Immunol 38(10): 2886-2895.
  10. Peacey, M., Wilson, S., Perret, R., Ronchese, F., Ward, V. K., Young, V., Young, S. L. and Baird, M. A. (2008). Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response. Vaccine 26(42): 5334-5337.
  11. Perret, R. and Ronchese, F. (2008). Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours? Tissue Antigens 72(3): 187-194.
  12. van Panhuys, N., Perret, R., Prout, M., Ronchese, F. and Le Gros, G. (2005). Effector lymphoid tissue and its crucial role in protective immunity. Trends Immunol 26(5): 242-247.
    *These authors contributed equally to the work
Protocols by Rachel Perret
  1. Vaccine-induced Cytokine Production Detected by Luminex Multiplex Analysis
  2. Analysis of Tumor-infiltrating Lymphocytes Following CD45 Enrichment